Sanofi to Provide COVID-19 Vaccine Manufacturing Support to BioNTech

France-based Sanofi and Germany-based BioNTech announced they have today entered into an agreement under which Sanofi will support the manufacturing and supply of BioNTech’s Comirnaty COVID-19 vaccine, which is being co-developed with Pfizer.

Sanofi will provide BioNTech access to its established infrastructure and expertise to produce over 125 million doses of the Comirnaty COVID-19 vaccine in Europe. Initial supplies will originate from Sanofi’s production facilities in Frankfurt from the summer of 2021.

Paul Hudson, the CEO of Sanofi, stated in a press release issued on January 27, 2021, “Although vaccination campaigns have started around the world, the ability to get shots into arms is being limited by lower than expected supplies and delayed approval timelines owing to production shortages. We have made the decision to support BioNTech and Pfizer in manufacturing their COVID-19 vaccine in order to help address global needs, given that we have the technology and facilities to do so."

"As always, our top priority is to focus our efforts and capabilities on fighting this global pandemic. First and foremost, we will do this by continuing to develop our own COVID-19 vaccine candidates, in parallel with this industrial cooperation.”